ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

ESMO Exclusive Interview | Professor HuiyanLuo : Significant Efficacy of the Combination of Anti-PD-L1/TGF-βRII Dual-Target Antibody SHR-1701 with Bevacizumab in the Treatment of Advanced Solid Tumors

2023.12.01
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place from October 20th to 24th in Madrid, Spain. The Oncology Insights Reporting Team delved deep into the front lines to witness international advancements and to witness the progress of China's anti-tumor efforts on the global stage. Professor Huiyan Luo from Sun Yat-sen University Cancer Center presented a crucial oral presentation (Abstract ID: 1026MO) at this conference. In this on-site interview, Professor Huiyan Luo shared insights into the study of the treatment of advanced solid tumors using the dual-target antibody SHR-1701, which targets PD-L1 and TGF-βRII, in combination with the VEGF inhibitor bevacizumab, as well as her thoughts on future directions for the treatment of advanced tumors. This article compiles the relevant content for readers.
ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients

ESMO Big Shot Interview | pCR reaches 39.8%, short-course radiotherapy followed by cetuximab in combination with CAPOX brings significant benefits to locally advanced rectal cancer patients

2023.11.27
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain, from October 20th to 24th. Professor Tao Zhang and Professor Kaixiong Tao  from Tongji Medical College of Huazhong University of Science and Technology and their team conducted a randomized Phase III trial, the UNION study (Abstract Number: LBA25), entitled "Neoadjuvant Short-Course Radiotherapy Followed by Cetuximab in Combination with CAPOX vs. Long-Course Sequential Chemotherapy in the Treatment of Locally Advanced Rectal Cancer." The study was selected for presentation as a proffered paper at the ESMO conference. "Oncology Frontier" interviewed Professor Tao Zhang and Professor Kaixiong Tao , and they interpreted the UNION study from both internal medicine and surgery perspectives, sharing their insights and thoughts on perioperative treatment for rectal cancer. This issue compiles the relevant content for readers.
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

2023.11.27
Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought about a breakthrough in the survival of these late-stage patients. However, some recurrent metastatic patients may develop endocrine resistance, reducing the efficacy of treatment. The European Society for Medical Oncology (ESMO) 2023 Annual Congress, held in Madrid, Spain, on October 20, 2023, featured Professor Xiaojia Wang's poster presentation on the combination of anlotinib and fulvestrant (452P), providing new hope for these patients. Oncology Frontier invited Professor Xiaojia Wang from Zhejiang Cancer Hospital to share insights.
ESMO 2023 | Dr. Silke Gillessen: Biomarkers and Future Perspectives in Advanced Prostate Cancer

ESMO 2023 | Dr. Silke Gillessen: Biomarkers and Future Perspectives in Advanced Prostate Cancer

2023.11.06
Prostate cancer, a multifaceted disease, frequently progresses to an advanced stage, imposing substantial therapeutic challenges. This advanced phase comprises both metastatic and locally advanced forms, demanding innovative strategies for effective management. In recent years, the discovery and application of biomarkers have emerged as a pivotal driving force in guiding treatment decisions and elevating patient outcomes. This article will delve deeper into the fundamental challenges surrounding advanced prostate cancer, the pivotal role of biomarkers in determining treatment pathways, the utility of cutting-edge imaging techniques, and the exciting prospects of biomarker-based therapies.